Shannon Stott, PhD
Assistant Professor of Medicine
Center for Cancer Research
Explore the Stott Lab
The Stott laboratory is comprised of bioengineers, biologists and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, we are interested in using microfluidics, imaging, and biopreservation technologies to create tools that increase our understanding of cancer biology and of the metastatic process. The Stott laboratory has codeveloped innovative microfluidic devices that can isolate extraordinarily rare circulating tumor cells (CTCs) and extracellular vesicles (EVs) from the blood of cancer patients. New microfluidic tools are being developed to both manipulate and interrogate these cells and vesicles at a single particle level. We also look at tumor specimens using multispectral imaging, hoping that the exploration of the spatial relationships between immune cells and tumor tissue will help us better predict treatment response. Ultimately, we hope that by working in close partnership with the clinicians and cell biologists at the Mass General Cancer Center, we can create new tools that directly impact patient care.
Rapid technological advances in microfluidics, imaging and digital gene expression profiling are converging to present new capabilities for blood, tissue and single-cell analysis. Our laboratory is interested in taking these advances and creating new technologies to help build understanding of the metastatic process. Our research focus is on:
- the development and application of microfluidic devices and biomaterials for the isolation and characterization of extracellular vesicles
- the enrichment and analysis of CTCs at a single cell level
- novel imaging strategies to characterize tumor tissue, cancer cells, and extracellular vesicles
Extracellular Vesicle Isolation and Characterization
Extracellular vesicles (EVs), such as exosomes, microvesicles, and oncosomes, are small particles that bud off of cancer cells, with some cancer cells releasing up to thousands of EVs per day. Researchers have hypothesized that these EVs shed from tumors transport RNA, DNA and proteins that promote tumor growth, and studies have shown that EVs are present in the blood of most cancer patients. Ongoing work in my lab incorporates microfluidics and novel biomaterials to enrich cell-specific EVs from cancer patients, using as little as 1mL of plasma. Once isolated, we are exploring their protein and nucleic acid content to probe their potential as a less invasive biomarker.
Microfluidics for Circulating Tumor Cell Analysis
One of the proposed mechanisms of cancer metastasis is the dissemination of tumor cells from the primary organ into the blood stream. A cellular link between the primary malignant tumor and the peripheral metastases has been established in the form of CTCs in peripheral blood. While extremely rare, these cells provide a potentially accessible source for early detection, characterization and monitoring of cancers that would otherwise require invasive serial biopsies. Working in collaboration with Drs. Mehmet Toner, Shyamala Maheswaran and Daniel Haber, we have designed a high throughput microfluidic device, the CTC-Chip, which allows the isolation and characterization of CTCs from the peripheral blood of cancer patients. Using blood from patients with metastatic and localized cancer, we have demonstrated the ability to isolate, enumerate and molecularly characterize putative CTCs with high sensitivity and specificity. Ongoing projects include translating the technology for early cancer detection, exploring the biophysics of the CTC clusters, and the design of biomaterials for the gentle release of the rare cells from the device surface. We are also developing new strategies for the long term preservation of whole blood such that samples can be shipped around the world for CTC analysis.
High-Content and High-Throughput Imaging of Tumor Specimens
Tumors can be highly heterogeneous, and their surrounding stroma even more so. Traditionally, the tumor and surrounding cells are dissociated from the tissue matrix for high throughput analysis of each cell. While this allows for important information to be gained, the spatial architecture of the tissue and corresponding interplay between tumor and immune cells can be lost. The Stott lab is developing quantitative, robust analysis for individual cells within the tumor and neighboring tissue using multispectral imaging. We are using this technology alongside downstream imaging processing algorithms to interrogate signaling activity in cancer cells, immune cell infiltration into to the tumor and pEMT in cancer cells. These data will be used to gain an increased understanding in the relationship between pharmacologic measurements and clinical outcomes, ultimately leading to the optimization of patient therapy.
View a list of publications by researchers at the Stott Laboratory.
Rabe DC, Walker ND, Rustandy FD, Wallace J, Lee J, Stott SL†, Rosner MR†. Tumor Extracellular Vesicles Regulate Macrophage-Driven Metastasis through CCL5. Cancers. 13(14): 3459, 2021.
Tessier SN, Bookstaver LD, Angpraseuth C, Stannard CJ, Marques B, Ho UK, Muzikansky A, Aldikacti B, Reategui E, Rabe DC, Toner M, Stott SL. Isolation of intact extracellular vesicles from cryopreserved samples. PLoS One. 16(5):e0251290, 2021.
Tessier SN^, Weng L^, Moyo WD, Au SH, Wong KHK, Angpraseuth C., Stoddard AE, Lu C, Nieman LT, Sandlin RD, Uygun K, Stott SL^, Toner M^. Effect of Ice Nucleation and Cryoprotectants during High Subzero-Preservation in Endothelialized Microchannels. ACS Biomater Sci Eng. 4(8):3006-3015, 2019.
Reátegui E*, van der Vos KE*, Lai CP*, Zeinali M, Atai NA, Floyd FP, Khankhel A, Thapar V, Toner M, Hochberg FH, Carter B, Balaj L, Ting DT, Breakefield XO, Stott SL. Engineered Nanointerfaces for Microfluidic Isolation and Molecular Profiling of Tumor-specific Extracellular Vesicles. Nat. Comm. 2018; 9(1).
Wong K.H.K.*, Tessier S.N.*, Miyamoto D., Miller K.L., Bookstaver L.D., Carey T.R., Stannard C., Tai E.C., Vo K.D., Sandlin R.D., Thapar V., Sequist L.V., Ting D.T., Haber D.A., Maheswaran S., Stott S.L. †, Toner M†. Whole blood stabilization for precision oncology: isolation and molecular characterization of circulating tumor cells. Nat. Comm., 2017 8(1). .
Park M.H.*, Reátegui E*, Li W., Jensen A.E., Toner M, Stott S.L.†, Hammond P.T. †. Enhanced Isolation and Release of Circulating Tumor Cells Using Nanoparticle Binding in a Microfluidic Chip Via Place-Exchangeable Ligands. JACS, 139(7) 2017.
Reátegui E. Aceto N. Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist L.V, Haber D A, Maheswaran S, Hammond PT, Toner M, Stott SL. Nanostructured coating for immunoaffinity capture and selective release of single viable circulating tumor cells. Advanced Materials 27 (9), 2015.
Multispectral image of a section of tumor tissue from a patient with head and neck cancer. Various markers were selected for cell identification to explore the relationship between immune cells and cancer cells within the tumor.
Shannon Stott, PhDPrincipal Investigator
- Sara Cavallaro, PhD
- Adarsh Choudhury
- Tishayne Diaz
- Nicola Hartmann
- Uyen Ho, BA
- Dasol Lee, BA
- Evelyn Luciani, BS
- Samantha Martin, MD
- Avanish Mishra, PhD***
- Daniel Rabe, PhD
- Michael Rimmer, MD
- Daniel Ruiz-Torres, MD*
- Sara Veiga, PhD
- Jillian Wise, PhD**
*Co-mentored with Daniel Faden, MD
**Co-mentored with Michael Lawrence, PhD
***Co-mentored with Mehmet Toner, PhD
Center for Cancer Research
The scientific engine for discovery for the Mass General Cancer Center.
Support the Center for Cancer Research
When you support the Center for Cancer Research you are enabling discoveries that will lead to effective new weapons in the battle against cancer.
participated in Clinical Trials at the Mass General Cancer Center last year
This helped lead to new knowledge and breakthrough therapies.